IOVAIovance Biotherapeutics, Inc.Signing up patients
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Unresectable Melanoma · Metastatic Melanoma · Stage III Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 53 (planned)
- Started
- Jul 20, 2022
- Main results expected
- Sep 2027
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase I: Safety of IOV-4001
Measured over: Up to 1 Year or depending on when the recommended phase 2 dose is determined
Phase 2: Objective Response Rate (ORR)
Measured over: Up to 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05361174 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC